Published in J Neurovirol on December 19, 2012
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. Nat Rev Neurol (2016) 1.71
Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med (2013) 1.04
Cognitive neurorehabilitation of HIV-associated neurocognitive disorders: a qualitative review and call to action. Neuropsychol Rev (2013) 0.95
Interventions to reduce alcohol use among HIV-infected individuals: a review and critique of the literature. Curr HIV/AIDS Rep (2013) 0.92
HIV and neurocognitive dysfunction. Curr HIV/AIDS Rep (2013) 0.91
Real-world impact of neurocognitive deficits in acute and early HIV infection. J Neurovirol (2013) 0.90
Host genetic factors predisposing to HIV-associated neurocognitive disorder. Curr HIV/AIDS Rep (2014) 0.88
Neuroimmune basis of methamphetamine toxicity. Int Rev Neurobiol (2014) 0.86
Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection. AIDS (2014) 0.86
Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressive ART. Sci Rep (2015) 0.84
HIV-1 transgenic female rat: synaptodendritic alterations of medium spiny neurons in the nucleus accumbens. J Neuroimmune Pharmacol (2014) 0.84
Dopamine receptor activation increases HIV entry into primary human macrophages. PLoS One (2014) 0.84
Alcohol Use and Human Immunodeficiency Virus (HIV) Infection: Current Knowledge, Implications, and Future Directions. Alcohol Clin Exp Res (2016) 0.83
Detrimental impact of remote methamphetamine dependence on neurocognitive and everyday functioning in older but not younger HIV+ adults: evidence for a legacy effect? J Neurovirol (2014) 0.81
Dopamine increases CD14+CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis. PLoS One (2015) 0.79
A history of alcohol dependence augments HIV-associated neurocognitive deficits in persons aged 60 and older. J Neurovirol (2014) 0.79
Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models. J Neuroimmune Pharmacol (2016) 0.78
Neurobehavioral Disturbances During Acute and Early HIV Infection. Cogn Behav Neurol (2016) 0.77
HIV-1 Tat and cocaine mediated synaptopathy in cortical and midbrain neurons is prevented by the isoflavone Equol. Front Microbiol (2015) 0.75
Dopamine Increases CD14(+)CD16(+) Monocyte Transmigration across the Blood Brain Barrier: Implications for Substance Abuse and HIV Neuropathogenesis. J Neuroimmune Pharmacol (2017) 0.75
Abbreviated Goal Management Training Shows Preliminary Evidence as a Neurorehabilitation Tool for HIV-associated Neurocognitive Disorders among Substance Users. Clin Neuropsychol (2016) 0.75
Dual-mixed HIV-1 coreceptor tropism and HIV-associated neurocognitive deficits. J Neurovirol (2013) 0.75
Mobile technology intervention to improve care coordination between HIV and substance use treatment providers: development, training, and evaluation protocol. Addict Sci Clin Pract (2017) 0.75
Contextualizing Psychosocial Determinants of Alcohol Use by Age Cohorts of Adults Living With HIV, Ages 50 and Older. J Assoc Nurses AIDS Care (2016) 0.75
The impact of age, HIV serostatus and seroconversion on methamphetamine use. Am J Drug Alcohol Abuse (2016) 0.75
Phosphatidylethanol (PEth) as a Biomarker of Alcohol Consumption in HIV-Infected Young Russian Women: Comparison to Self-Report Assessments of Alcohol Use. AIDS Behav (2017) 0.75
Longitudinal Modeling of Depressive Trajectories Among HIV-Infected Men Using Cocaine. AIDS Behav (2017) 0.75
Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction (1993) 41.55
CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med (2004) 13.55
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology (2010) 12.32
The drug abuse screening test. Addict Behav (1982) 9.55
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc (2004) 6.64
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Biological and virologic characteristics of primary HIV infection. Ann Intern Med (1998) 5.45
Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol (2004) 4.90
The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res (2007) 4.84
Does alcohol lead to sexual risk behavior? Findings from event-level research. Annu Rev Sex Res (2000) 4.61
Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med (2003) 3.81
The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr (2007) 3.76
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev (2007) 3.57
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc (2004) 3.21
A comprehensive review of the psychometric properties of the Drug Abuse Screening Test. J Subst Abuse Treat (2006) 3.01
Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol (2007) 2.62
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Diagnostic validity of the drug abuse screening test in the assessment of DSM-III drug disorders. Br J Addict (1989) 2.32
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol (2004) 2.22
Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology (2009) 2.08
Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol (2011) 2.06
Prospective memory in HIV-1 infection. J Clin Exp Neuropsychol (2006) 1.99
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Diagnosis and management of acute HIV infection. Infect Dis Clin North Am (2007) 1.91
Adult and geriatric normative data and validation of the profile of mood states. J Clin Psychol (1999) 1.91
Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology (2009) 1.83
Action (verb) fluency: test-retest reliability, normative standards, and construct validity. J Int Neuropsychol Soc (2005) 1.65
Neurocognitive complaints in HIV-infection and their relationship to depressive symptoms and neuropsychological functioning. J Clin Exp Neuropsychol (1999) 1.55
Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev (2009) 1.54
Abnormalities in resting-state functional connectivity in early human immunodeficiency virus infection. Brain Connect (2011) 1.52
Natural history of neuropsychiatric manifestations of HIV disease. Psychiatr Clin North Am (1994) 1.43
Methamphetamine enhances cell-associated feline immunodeficiency virus replication in astrocytes. J Neurovirol (2002) 1.35
Deficient strategic control of verbal encoding and retrieval in individuals with methamphetamine dependence. Neuropsychology (2005) 1.33
The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug Alcohol Depend (2008) 1.33
Neurocognitive functioning in acute or early HIV infection. J Neurovirol (2010) 1.27
Strategies used in the detection of acute/early HIV infections. The NIMH Multisite Acute HIV Infection Study: I. AIDS Behav (2009) 1.26
Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology (2006) 1.23
Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol (2003) 1.22
Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care (2012) 1.21
Alterations in brain metabolism during the first year of HIV infection. J Neurovirol (2011) 1.20
Psychiatric context of acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: IV. AIDS Behav (2009) 1.20
Alcoholism, HIV infection, and their comorbidity: factors affecting self-rated health-related quality of life. J Stud Alcohol Drugs (2007) 1.13
Neurocognitive deficits are associated with unemployment in chronic methamphetamine users. Drug Alcohol Depend (2012) 1.09
Psychological distress, drug and alcohol use as correlates of condom use in HIV-serodiscordant heterosexual couples. AIDS (1993) 1.06
Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis (2000) 1.01
Implications of apathy for everyday functioning outcomes in persons living with HIV infection. Arch Clin Neuropsychol (2012) 0.99
Severity of psychiatric symptoms after HIV testing. Am J Psychiatry (1993) 0.98
Planning deficits in HIV-associated neurocognitive disorders: component processes, cognitive correlates, and implications for everyday functioning. J Clin Exp Neuropsychol (2012) 0.89
Drinking your troubles away: the role of activity in mediating alcohol's reduction of psychological stress. J Abnorm Psychol (1986) 0.80
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc (2004) 6.64
Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (2004) 5.18
Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol (2004) 4.90
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev (2007) 3.57
Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc (2004) 3.21
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat (2002) 3.13
Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol (2004) 3.12
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis (2006) 2.88
Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev (2009) 2.86
Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69
Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol (2009) 2.51
The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell (2004) 2.46
Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis (2011) 2.44
Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry (2005) 2.34
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol (2006) 2.33
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS (2011) 2.31
Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol (2002) 2.28
Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol (2007) 2.27
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26
Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis (2006) 2.26
Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol (2004) 2.22
Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis (2003) 2.16
Neurologic complications of HIV disease and their treatment. Top HIV Med (2010) 2.14
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS (2005) 2.07
Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J Clin Exp Neuropsychol (2011) 2.06
Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol (2007) 2.03
Role of seminal shedding of herpesviruses in HIV Type 1 Transmission. J Infect Dis (2012) 1.99
HIV-associated prospective memory impairment increases risk of dependence in everyday functioning. Neuropsychology (2008) 1.99
Prospective memory in HIV-1 infection. J Clin Exp Neuropsychol (2006) 1.99
Timing is everything: antiretroviral nonadherence is associated with impairment in time-based prospective memory. J Int Neuropsychol Soc (2009) 1.94
Incidence of HIV superinfection following primary infection. JAMA (2004) 1.92
Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.91
Measurement and predictors of resilience among community-dwelling older women. J Psychiatr Res (2008) 1.91
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
Phenotypic anchoring of gene expression changes during estrogen-induced uterine growth. Environ Health Perspect (2004) 1.84
Sleep in spousal caregivers of people with Alzheimer's disease. Sleep (2005) 1.83
Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol (2006) 1.82
Female methamphetamine users: social characteristics and sexual risk behavior. Women Health (2004) 1.81
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS (2002) 1.78
A longitudinal study of the use of mental health services by persons with serious mental illness: do Spanish-speaking Latinos differ from English-speaking Latinos and Caucasians? Am J Psychiatry (2007) 1.78
Serosorting can potentially increase HIV transmissions. AIDS (2007) 1.78
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med (2010) 1.76
Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol (2011) 1.73
Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology (2006) 1.71
Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS (2013) 1.71
The need for treatment interruption studies and biomarker identification in the search for an HIV cure. AIDS (2015) 1.68
The global transmission network of HIV-1. J Infect Dis (2013) 1.68
Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (2014) 1.67
The context of sexual risk behavior among heterosexual methamphetamine users. Addict Behav (2004) 1.67
Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS (2010) 1.66
Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol (2004) 1.65
Action (verb) fluency: test-retest reliability, normative standards, and construct validity. J Int Neuropsychol Soc (2005) 1.65
Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol (2008) 1.64
Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies? Immunology (2009) 1.64
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis (2007) 1.63
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol (2005) 1.62
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology (2013) 1.62
HIV-specific cytotoxic T cells from long-term survivors select a unique T cell receptor. J Exp Med (2004) 1.60
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60